News | September 28, 2022
LISSUN raises ~$1 million in pre-Seed round from IvyCap Ventures and others
Funds raised will be used to develop technology and foster healthcare partnerships
Funds raised will be used to develop technology and foster healthcare partnerships
The second day of Arogya Manthan 2022 had panel discussions with eminent thought leaders from relevant public and private sector organizations
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
Transformation to pure-play Innovative Medicines company nears completion
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Subscribe To Our Newsletter & Stay Updated
